AB0485 Anti-C1q Antibodies in Systemic Lupus Erythematosus and Its Correlation with Renal Pathology of Lupus Nephritis

Background There is a lack of serum markers for effective evaluation of renal lesion severity of systemic lupus erythematosus (SLE). Recent studies show that anti-Clq antibody has been associated with SLE and lupus nephritis (LN), but there were few data about the relationship between anti-Clq antibody and renal pathology of LN. Objectives To investigate the relationship between serum anti - Clq antibody and the disease activity of SLE as well as renal pathological characteristic. Methods Anti-C1q Ab were measured by enzyme-linked immunosorbant assay (ELISA) in 128 patients with SLE (including 58 cases with LN and 70 cases without LN), 103 patients with other autoimmune diseases (disease control group) and 60 healthy individuals (healthy control group). Renal biopsy was conducted in all LN patients. Results Prevalence of anti-C1q was 31.3% (40/128) in patients with SLE, significantly higher than that in disease control group and healthy control group (31.3% vs.4.9% (5/103), P Conclusions The serum anti-C1q antibody, a simple and non-invasive marker, can reflect the disease activity of SLE, especially with regard to renal involvement. It is useful for SLE to predict renal lesion, particularly diffuse proliferative LN (iclass IV). References Trendelenburg M, Lopez Trascasa M, Potlukova E, et al. High prevalence of anti-C1q antibodies in biopsy-proven active lupus nephritis. Nephrol Dial Transplant, 2006, 21(11):3115. Horak P, Hermanova Z, Zadrazil J, et al. C1q complement component and antibodies reflect SLE activity and kidney involvement. Clin Rheumatol, 2006, 25(4):532 -536. L. Gargiulo Mde, G. G9omez, M. Khoury et al. Association between the presence of anti-C1q antibodies and active nephritis in patients with systemic lupus erythematosus, Medicina,vol. 75, no. 1, pp. 23–28, 2015. Disclosure of Interest None declared